Literature DB >> 17301437

High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis.

Mohammad Hassan Bemanian1, Masoud Movahedi, Abolhassan Farhoudi, Mohammad Gharagozlou, Mehran Heidari Seraj, Zahra Pourpak, Mohammad Nabavi, Asghar Aghamohammadi, Zahra Shirkhoda.   

Abstract

Atopic dermatitis is one of the most common allergic diseases that almost always respond to conventional therapies with topical emollient, topical corticosteroids, systemic antihistamines and allergic abstinence. However few cases of atopic dermatitis with severe course do not respond to conventional therapies and high dose of intravenous immunoglobulin or cyclosporine are recommended for them. This clinical trial study has been done to compare the last two regimens in patients with severe atopic dermatitis, Scoring Atopic Dermatitis (SCORAD) greater than 70. We included 14 patients in two groups. In group 1, eight patients were randomly selected and received 4mg/kg cyclosporine daily for 3 months and in group 2, six patients received 2g/kg Intravenous Immunoglobulin (IVIG) as stat infusion. All patients were followed on days 15, 30, 60 and 90 after starting the therapy. About 75% and 62.5% of patients had positive skin tests to egg and to milk respectively. Six patients out of 14 patients did not have skin test, so specific IgE by Radioallergosobent tests (RAST) was used for them. All of these patients had positive RAST to egg and 66.6% against cow's milk. There was a significant difference in the clinical outcomes of these two groups with a marked reduction in SCORAD of day 90th in group 1 in comparison to group 2 (P-value = 0.005). No significant adverse drug reaction was seen in these two groups.

Entities:  

Year:  2005        PMID: 17301437     DOI: 04.03/ijaai.139143

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  8 in total

1.  Update on the management of chronic eczema: new approaches and emerging treatment options.

Authors:  Hobart W Walling; Brian L Swick
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-07-28

Review 2.  Allergen-specific IgG as a mediator of allergy inhibition: Lessons from mother to child.

Authors:  Jefferson Russo Victor
Journal:  Hum Vaccin Immunother       Date:  2016-11-03       Impact factor: 3.452

Review 3.  Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?

Authors:  Helen Alexander; Thomas Patton; Zarif K Jabbar-Lopez; Andrea Manca; Carsten Flohr
Journal:  F1000Res       Date:  2019-01-31

4.  Consensus Update for Systemic Treatment of Atopic Dermatitis.

Authors:  Ji Hyun Lee; Jung Eun Kim; Gyeong-Hun Park; Jung Min Bae; Ji Yeon Byun; Min Kyung Shin; Tae Young Han; Seung Phil Hong; Yong Hyun Jang; Hye One Kim; Chan Ho Na; Bark-Lynn Lew; JiYoung Ahn; Chang Ook Park; Young-Joon Seo; Yang Won Lee; Sang Wook Son; Eung Ho Choi; Young Lip Park; Joo Young Roh
Journal:  Ann Dermatol       Date:  2021-11-04       Impact factor: 1.444

5.  Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.

Authors:  Aaron M Drucker; Deanna E Morra; David Prieto-Merino; Alexandra G Ellis; Zenas Z N Yiu; Bram Rochwerg; Sonya Di Giorgio; Bernd W M Arents; Tim Burton; Phyllis I Spuls; Jochen Schmitt; Carsten Flohr
Journal:  JAMA Dermatol       Date:  2022-05-01       Impact factor: 11.816

Review 6.  Advances in the diagnosis and therapeutic management of atopic dermatitis.

Authors:  Christian Vestergaard; Mette Deleuran
Journal:  Drugs       Date:  2014-05       Impact factor: 11.431

7.  Systemic treatments for eczema: a network meta-analysis.

Authors:  Ratree Sawangjit; Piyameth Dilokthornsakul; Antonia Lloyd-Lavery; Nai Ming Lai; Robert Dellavalle; Nathorn Chaiyakunapruk
Journal:  Cochrane Database Syst Rev       Date:  2020-09-14

8.  Biologics in dermatology.

Authors:  David Chandler; Anthony Bewley
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.